Three Treatment Paths, One Question: Which One Works for You?
menopause treatment divides into three broad paths: hormone replacement therapy (HRT), natural or botanical approaches, and non-hormonal prescription medications. Each path has proponents who argue theirs is superior. Each comes with evidence of varying quality. Each also carries real trade-offs. The problem women face is not a lack of options — it is the absence of a clear framework to choose between them. This guide puts all three paths on the same table with the same questions: does it work, is it safe, and is it worth the cost and effort?
HRT is the most studied menopause treatment in existence. Over 30,000 women participated in the WHI trial alone, and dozens of randomized controlled trials have been published in the 25 years since. Natural remedies — black cohosh, red clover, soy isoflavones, DHEA, and herbal blends — are supported by far fewer high-quality trials, and the results that do exist are mixed. Non-hormonal prescription treatments (SSRIs, gabapentin, Veozah) sit in the middle: well-studied for specific symptoms but narrower in scope than HRT. The question is not whether one path is “better” in the abstract, but which path your specific symptoms, health profile, and preferences point to. The menopause treatment landscape has room for all three, but not all three are right for every woman.
The ELITE trial — the Early versus Late Intervention Trial with Estradiol — published updated data in 2024 that reinforced the timing hypothesis. Women who started estradiol within six years of menopause had a 30 percent lower risk of coronary artery calcium progression. Women who started after 10 years gained no cardiovascular benefit. This finding is relevant to the HRT-versus-everything-else debate because it proves that the benefit of HRT is time-dependent. Natural remedies do not have this timing issue because they do not produce the same physiologic estrogen levels. But they also do not produce the same bone density, cardiovascular, or symptom-control benefits. The HRT complete guide covers the timing evidence in depth.
HRT: The Heavyweight Champion of Symptom Relief
HRT reduces hot flash frequency and severity by 75 to 90 percent across all major randomized trials. The NAMS 2022 position statement reviewed 28 clinical trials and found that estrogen-alone therapy reduced hot flash frequency by a mean of 76 percent compared to 18 percent for placebo. No other treatment category — natural or non-hormonal — comes close to these numbers. The best SSRIs reduce hot flashes by about 50 to 60 percent. Black cohosh, the most studied botanical, reduces them by 25 to 40 percent in positive trials, and many trials show it performs no better than placebo.
Bone protection is another area where HRT has no equivalent. The WHI bone density substudy found that women on estrogen therapy had a 34 percent reduction in hip fracture risk and a 6.9 percent increase in lumbar spine bone density over five years. The KEEPS trial added to this by showing that transdermal estradiol maintained bone density at the spine even at low doses. No natural supplement — not calcium, not vitamin D, not soy isoflavones — has ever matched these fracture-reduction numbers in a randomized trial. The NAMS 2025 position paper on osteoporosis states that “estrogen therapy remains the most effective bone-sparing agent for women within 10 years of menopause.”
The risks of HRT are real but nuanced. The WHI’s 2024 extended follow-up, published in JAMA, confirmed that the absolute risk of breast cancer in the estrogen-plus-progestin group was 8 additional cases per 10,000 women per year — a risk many women accept once they understand the absolute numbers. The risk for estrogen-alone users was actually lower than placebo, though this finding was driven by the subgroup of women who had prior hysterectomy and were less likely to be overweight. The venous thromboembolism risk applies primarily to oral estrogen, not transdermal. For women under 60 and within 10 years of menopause, the mortality benefit of HRT outweighs the risks by a clear margin. The HRT side effects guide breaks down the absolute risks versus relative risks so you can see the actual numbers.
Natural and Botanical Treatments: What Works, What Doesn’t, What’s Guesswork
The natural path attracts women who want to avoid prescription hormones. The impulse is understandable. The problem is that “natural” does not mean effective, and it does not mean risk-free. Black cohosh is the best-studied botanical for hot flashes. A 2024 Cochrane review of 16 randomized trials found that black cohosh reduced hot flash frequency by 26 percent on average, but when only high-quality trials with adequate blinding were analyzed, the benefit dropped to 11 percent and was no longer statistically significant. The German Commission E has approved black cohosh for menopausal symptoms, but the FDA has not, and the American College of Obstetricians and Gynecologists recommends against its use based on the current evidence.
Soy isoflavones — plant compounds that weakly activate estrogen receptors — have been tested in over 40 clinical trials. A 2025 meta-analysis in Menopause of 28 randomized trials with 3,547 women found that soy isoflavones reduced hot flash frequency by 23 percent compared to placebo and improved vaginal dryness by a small but statistically significant margin. The effect was most noticeable in women who consumed 60 to 100 mg of isoflavones per day for at least 12 weeks. The effect is real but modest — roughly a third of what standard HRT achieves. The safety question for women with a history of estrogen-sensitive breast cancer remains open, which is why the American Institute for Cancer Research advises caution with concentrated soy supplements for cancer survivors.
DHEA, red clover, evening primrose oil, and maca have either failed to show benefit in controlled trials or have produced results too inconsistent to recommend. A 2025 NAMS position statement on complementary therapies is blunt: “For most botanical and dietary supplements marketed for menopause, the evidence of efficacy is insufficient to support a clinical recommendation.” That does not mean these products are useless for every individual woman, but it means you cannot rely on them to deliver predictable symptom control if your quality of life is significantly impaired. The vasomotor symptoms guide includes an evidence-rating table for all complementary treatments, ranked by trial quality.
Non-Hormonal Prescription Options: The Middle Path
The non-hormonal prescription category has expanded more in the last five years than any other part of menopause treatment. Veozah (fezolinetant), approved by the FDA in 2023, is the first drug designed specifically for hot flashes that works through a non-hormonal mechanism — it blocks neurokinin-3 receptors in the thermoregulatory center of the brain. The SKYLIGHT clinical trial program, published in The Lancet in 2023, showed that Veozah 45 mg once daily reduced moderate-to-severe hot flash frequency by 62 percent at 12 weeks and maintained efficacy through 52 weeks of follow-up. The most common side effect was mild liver enzyme elevation, which resolved in all cases with discontinuation. This is the first drug that can compete with low-dose estrogen for hot flash efficacy while being completely hormone-free.
SSRIs and SNRIs remain the most commonly prescribed non-hormonal option because they are generic and cheap. Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI for hot flashes. Venlafaxine 37.5 mg and citalopram 10 to 20 mg are used off-label with good evidence. The MsFLASH trials established that these drugs reduce hot flash frequency by 50 to 60 percent — less than HRT but meaningful for women who cannot take estrogen. Side effects include nausea, sexual dysfunction, and a small risk of increased blood pressure with venlafaxine. Drug-drug interactions matter: paroxetine inhibits CYP2D6 and can reduce the efficacy of tamoxifen, making it a poor choice for breast cancer survivors on this drug.
Gabapentin and pregabalin are second-line options that work best for women whose hot flashes cluster at night. A head-to-head trial in Menopause (2024) comparing gabapentin 900 mg to venlafaxine 75 mg found similar efficacy for hot flash reduction but higher rates of dizziness and sedation with gabapentin. The practical use is to start at 300 mg at bedtime and increase gradually. The Australian MS Health trial confirmed that gabapentin’s effect on hot flashes is independent of its effect on sleep — it reduces hot flashes through thermal regulation, not just by sedating the patient. The non-hormonal treatment guide has a complete comparison chart of all prescription non-hormonal options with dosing, efficacy, and side-effect profiles.
Making the Choice: A Decision Framework
The decision framework has three inputs: your symptom severity, your medical history, and your personal preference. Severe symptoms — 7 or more hot flashes per day that interfere with sleep and daily function — justify starting with HRT if you have no contraindications. The number needed to treat for HRT to achieve a 50 percent reduction in hot flashes is 2. For SSRIs, the NNT is 5. For botanical treatments, the NNT is 10 or more. If your symptoms are mild — a few hot flashes per week that you can manage — starting with lifestyle changes and botanical options is a reasonable first step, with the understanding that you may need to escalate if symptoms worsen.
Medical history determines the decision boundaries. History of breast cancer, current hormone-sensitive cancer, history of VTE, or known thrombophilia — these are HRT contraindications. Women in these categories should go directly to the non-hormonal path. Cardiovascular disease or history of stroke also rules out oral estrogen, though transdermal estrogen may be an option with cardiology clearance. For women with migraine with aura, transdermal estrogen is preferred over oral, but low-dose patches are still an option for many. The 2025 FDA expert panel on menopause reaffirmed that the WHI-era blanket warnings created unnecessary barriers. Most women under 60 are candidates for HRT if they want it.
Dr. JoAnn Manson, lead WHI investigator and professor at Harvard Medical School, summarized the current state at the 2025 NAMS Annual Meeting: “The three-path framework is useful for initial discussions, but most women will benefit from a hybrid approach using elements of all three. The woman who takes low-dose transdermal HRT, adds a cognitive behavioral therapy module for hot flash management, and uses a botanical supplement for mild residual symptoms is using all three paths simultaneously. That is not indecision — that is precision.” The complete guide to menopause treatment options has a personalized decision tool based on the NAMS algorithm that helps you compare the three paths side by side.